GLP-1 Medications

The most powerful metabolic
tool in a generation.
With the oversight it requires.

GLP-1 receptor agonists have transformed metabolic medicine. The question is whether you're using them with the clinical depth they actually demand.

Considering GLP-1s? Currently on Ozempic or Wegovy? Managing post-GLP-1 rebound?

Schedule a Meeting Full Metabolic Programme

Metabolic Trajectory — With vs. Without Oversight

Clinical Context

What the headlines
don't tell you.

GLP-1 receptor agonists are genuine breakthroughs. They are also genuinely misused in the absence of proper oversight.

The Promise

GLP-1 receptor agonists represent the most significant advance in metabolic pharmacology in decades. The clinical data on weight reduction, cardiovascular risk, and metabolic improvement are extraordinary and well-documented.

The Risk Without Oversight

GLP-1s reduce total mass — not just fat. Without structured resistance training protocols and adequate protein targets, a significant portion of weight lost is lean muscle mass. This worsens metabolic rate long-term.

The Rebound Problem

Most GLP-1 courses end without a structured exit protocol. Appetite returns. Without underlying lifestyle change and a taper plan, rebound is the statistical norm — and the starting position is often worse than before.

The Breeoot Approach

Three phases.
One continuous picture.

Most GLP-1 prescriptions in Israel consist of a consultation and a 6-month check-in. Breeoot treats GLP-1 management as a clinical programme.

Phase 01

Baseline Assessment

Before any prescription, we establish where your metabolism actually is.

→Full metabolic panel: HOMA-IR, fasting insulin, HbA1c, ApoB, Lp(a), hs-CRP

→Body composition: DEXA scan — visceral fat, lean muscle mass baseline

→Hormonal context: thyroid, sex hormones, cortisol

→Continuous glucose monitoring (CGM): baseline glucose dynamics

→Functional fitness baseline: VO₂ max, grip strength

This baseline is the document that everything else is measured against.

Phase 02

Active Management

While you're on the medication, we're watching the numbers — not waiting for your next appointment.

→Monthly check-ins with your Personal Doctor

→CGM tracking throughout: glucose response to diet, exercise, dose

→Lean mass protection: nutrition targets, resistance training framework

→Dose titration guidance: evidence-based adjustment to your response

→Inflammatory and cardiovascular markers at 3-month intervals

Most people on GLP-1s in Israel have a prescription and a six-month check-in. That is not oversight.

Phase 03

Structured Exit Protocol

How you come off matters as much as how you go on.

→Taper timeline calibrated to your metabolic response

→Lifestyle protocol that sustains improvements independently

→Exit biomarker panel: comparing to baseline — what changed, what needs attention

→6-month post-exit monitoring: catching rebound early, adjusting if needed

The exit is where most GLP-1 courses fail. We treat it as a clinical milestone.

Clinical Authority

Led by Israel's foremost
GLP-1 clinician.

Prof. Amir Tirosh, MD PhD, is Director of the Institute of Endocrinology and Metabolism at Sheba Medical Center. His research on GLP-1 receptor agonist mechanisms, insulin resistance, and metabolic disease progression has been published in The New England Journal of Medicine, Nature Medicine, The Lancet, and JAMA.

He has trained hundreds of endocrinologists across Israel. When a GLP-1 case is complex, hospitals call him.

"The question was never whether GLP-1s work. It is whether they are being used with the depth of management they require."

— Prof. Amir Tirosh, MD PhD

NEJM · Nature Medicine · The Lancet · JAMA · Sheba Medical Center · Hebrew University Schedule a Meeting

Prof. Amir Tirosh

MD PhD · Co-Founder & CMO
Director, Endocrinology & Metabolism, Sheba

New England Journal of Medicine

GLP-1 mechanisms & metabolic disease progression

Nature Medicine

GLP-1 receptor agonist clinical outcomes

The Lancet & JAMA

Cardiovascular risk & insulin resistance

Sheba Medical Center

Israel's premier academic medical centre

Is This For You?

Three situations
where we can help.

Breeoot's GLP-1 programme is structured around the three moments when clinical oversight changes outcomes.

Situation 01

Considering GLP-1s

You're hearing about Ozempic and Wegovy. Your metabolic markers might make them clinically appropriate. You want to understand, before you start, what doing it properly actually looks like.

What we do Full baseline assessment, shared decision-making within Prof. Tirosh's framework, a programme designed to maximise outcomes while protecting lean mass.

Situation 02

Currently on a GLP-1

You're already on semaglutide or tirzepatide — perhaps prescribed elsewhere. You're seeing results but have questions. Nobody is monitoring the full picture.

What we do Mid-programme onboarding — establishing your current metabolic state, adding the monitoring layer your prescription is missing, and integrating you into the ongoing management protocol.

Situation 03

Post-GLP-1 / Rebound

You came off a GLP-1 and the weight is returning. The underlying metabolic situation wasn't resolved. You want a clinical approach that addresses the root cause, not a repeat prescription.

What we do Full re-baseline, structured metabolic recovery plan — possibly including re-introduction with oversight, or non-pharmacological alternatives where appropriate.

GLP-1 is one tool.
Metabolism is the whole picture.

The Breeoot metabolic programme covers the full landscape — insulin dynamics, lipidology, inflammation, body composition, hormonal context, and functional fitness. GLP-1s are part of our pharmacological toolkit. For some members, they're the right tool. For others, they're not. The difference is an honest assessment.

Explore the full Metabolic Programme →

The most powerful metabolictool in a generation. With the oversight it requires.

What the headlinesdon't tell you.